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Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of serious
nosocomial infections, and recurrent MRSA infections primarily result from the survival
of persister cells after antibiotic treatment. Gas plasma, a novel source of ROS (reactive
oxygen species) and RNS (reactive nitrogen species) generation, not only inactivates
pathogenic microbes but also restore the sensitivity of MRSA to antibiotics. This study
further found that sublethal treatment of MRSA with both plasma and plasma-activated
saline increased the antibiotic sensitivity and promoted the eradication of persister cells
by tetracycline, gentamycin, clindamycin, chloramphenicol, ciprofloxacin, rifampicin, and
vancomycin. The short-lived ROS and RNS generated by plasma played a primary role
in the process and induced the increase of many species of ROS and RNS in MRSA
cells. Thus, our data indicated that the plasma treatment could promote the effects of
many different classes of antibiotics and act as an antibiotic sensitizer for the treatment
of antibiotic-resistant bacteria involved in infectious diseases.
Keywords: cold atmospheric-pressure plasma, antibiotics resistance, methicillin-resistant Staphylococcus
aureus, reactive oxygen species, reactive nitrogen species
INTRODUCTION
Antibiotics are the primary treatment for infectious bacterial diseases (Li et al., 2017). Antibiotic
resistance typically emerges several years after the development and use of a new antibiotic, usually
within an average of 8 years after introduction (Schmieder and Edwards, 2012). Furthermore,
infections with multidrug-resistant bacteria are occurring more frequently, and few or no drugs
are available to combat them (Boucher et al., 2009; Wright, 2016; Gonzalez-Bello, 2017). One of the
major multidrug-resistant bacteria is methicillin-resistant Staphylococcus aureus (MRSA), which is
recognized as a leading cause of nosocomial infections (Shahsavan et al., 2012; Emaneini et al.,
2017). Persisters are a small non-growing population of bacteria which could also escape from
different antibiotics (Levin and Rozen, 2006). Persisters extend the duration of antibiotic treatment,
cause the recurrence of infectious diseases, and the generation and ascent of antibiotic resistance
(Levin and Rozen, 2006). Increased antibiotic resistance and the shortage of new antibiotics
threaten global public health (Boucher et al., 2009; Dwyer et al., 2014). Therefore, strategies to
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combat antibiotic resistance, such as the development of new
antibiotics or prolonging the lifespan of current antibiotics, are
in high demand (Melander and Melander, 2017).
One strategy that has been explored recently is developing
approaches that induce bacterial killing via the same mechanism
as existing antibiotics. Antibiotics with different targets have
been proposed to share a common mechanism of bactericidal
activity—enhancing intracellular reactive oxygen species (ROS)
in bacterial cells (Kohanski et al., 2007, 2010). Although
ROS could be developed as antimicrobials to treat infectious
diseases, treatment with these highly reactive molecules is
problematic because ROS react non-selectively with such a
range of critical, macromolecular targets, which could lead to
“off-target” effects (Dharmaraja, 2017). Given that oxidative
stress is also associated with antibiotic treatment, low levels
of ROS could be used as an adjuvant to potentiate the
antibacterial activity of commercial antibiotics (Brynildsen et al.,
2013; Morones-Ramirez et al., 2013; Shen et al., 2016). A
previous study showed that •OH induced in Ag+-treated
bacteria potentiated the bactericidal activity of antibiotics
against bacterial persisters and biofilms (Morones-Ramirez et al.,
2013). Furthermore, fosfomycin, which acts by generating
O•−2 , was used to successfully treat MRSA infections when
combined with many commercial antibiotics (Shen et al.,
2016). These strategies relied on the addition of inorganic
or organic chemicals, which would bring residues after the
treatment.
Cold atmospheric-pressure plasma (referred to as “plasma”)
generates many reactive oxygen and nitrogen species (ROS and
RNS), such as H2O2,
1O2, O3,
•NO, and •OH as well as electrons,
ions, and photons. This form of plasma is atmospheric-pressure
and near room temperature, thus it treats cells and tissues
without thermal damage, making it attractive for a range of
biomedical applications, such as bacteria inactivation (Fridman
et al., 2008; Moreau et al., 2008; Kong et al., 2009; Kang et al.,
2014). The FDA has authorized the use of at least three gas
plasma-based products using “plasma biomedicine” technology,
such as blood coagulation. In addition, there have been several
phase-II clinical trials for plasma-based therapies, such as chronic
wound healing, which is the promising applications of plasma
in medicine (Isbary et al., 2010, 2012; Heinlin et al., 2013). In
the treatment of wounds, the reactive species of plasma could
not only kill the microorganisms in the infectious wounds and
burns but also increase proliferation of fibroblasts and other cells
(Lloyd et al., 2010). Bayliss et al. (2013) found that treatingMRSA
with sublethal doses of plasma restored the sensitivity ofMRSA to
trimethoprim, kanamycin, and oxacillin, but the utility of plasma
treatment with other types of antibiotics was not studied.
In the present study, in order to further our understanding
of the effect of plasma treatment on antibiotic sensitivity,
MRSA was treated with both plasma and plasma-activated saline
prior to exposure to multiple antibiotics. Sublethal treatment of
MRSA with plasma increased the sensitivity of MRSA to seven
antibiotics whilst also reducing the numbers of persisters. These
results support the use of plasma as an antibiotic sensitizer for the
treatment of antibiotic-resistant bacteria involved in infectious
diseases.
MATERIALS AND METHODS
Plasma Device and Plasma Treatments
As shown in Figure 1A, the surface discharge structure of the
plasma consisted of a high-voltage plane electrode, a liquid-facing
grounded mesh electrode of a hexagonal shape and a dielectric
layer (made of polytetrafluoroethylene) sandwiched between
the two electrodes. The surface plasma was generated when a
sinusoidal high voltage was applied and the discharge power
density was 0.2 W/cm2 with good mesh-to-mesh homogeneity
(showed in the front view of the plasmas in Figure 1A). One
milliliter MRSA suspension or saline in a Petri dish (diameter
35mm) with the depth of 1mm was placed under the plasma,
whereas the air gap between the plasma and the liquid surface
was about 8mm. The gas plasma system was housed in a sealed
organic glass box with a gas flow of helium and 1% artificial air
(79% N2 + 21% O2) at a constant rate of 4 L/min. The artificial
air was used as the source of ROS and RNS, while the helium was
used to enhance the production efficiency of those species as well
as their fluxes on the treated samples via diffusion.
Measurement of ROS and RNS Generated
by the Plasma




3 in 0.9% NaCl
were measured using hydrogen peroxide/peroxidase assay kit
(Thermo Fisher Scientific) and nitrite/nitrate colorimetric assay
kit (Cayman), respectively. •OH, 1O2,
•NO, O•−2 ,
•NO2, and
ONOO− were measured using an electron spin-resonance
(ESR) spectroscopy (Bruker) together with relevant spin traps.
The latter include: 100mM DMPO (5,5-Dimethyl-1-pyrroline
N-oxide, Dojindo), 5mM MGD (N-(Dithiocarbamoyl)-
N-methyl-D-glucamine, Dojindo), 10mM TEMP (2,2,6,6-
Tetramethylpiperidine, TCI), and 10mM TEMPONE-H
(1-Hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine, Enzo).
Treatment of Staphylococcus aureus With
Plasma or Plasma-Activated Saline
A single S. aureus ATCC33591 colony was grown in 4ml of
Mueller-Hinton (MH) broth (Oxoid) at 225 r.p.m. at 37◦C
overnight, and the resulting overnight culture was diluted 1:100
in MH and incubated at 37◦C at 225 r.p.m. until an OD600 of 0.6
was reached. The bacterial cells were collected by centrifugation,
washed once with saline (0.9%NaCl) and resuspended in saline at
an OD600 of 2.0. S. aureus suspensions were treated with plasma
directly, or the suspensions were centrifuged and resuspended
in plasma-activated saline (saline treated with plasma for the
indicated time), saline with 250µM H2O2 + 125µM NO
−
2
+ 375µM NO−3 , or saline with 500µM H2O2 + 250µM
NO−2 + 750µM NO
−
3 and then incubated for 30min at room
temperature. Samples were serially diluted with 0.9% NaCl, and
10 µl of each dilution was spotted onto MH agar plates and
incubated overnight at 37◦C and the numbers of surviving
bacteria were determined by counting the resulting CFUs.
Determination of Antibiotic Sensitivity
The S. aureus suspensions prepared as described above were
either untreated, treated with plasma directly for 30 or 40 s, or
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FIGURE 1 | Measurement of the ROS and RNS diffused into the saline treated with plasma. (A) Diagram of MRSA suspension or saline treated with plasma. (B) The
concentrations of ROS, RNS and spin trap adducts diffused into the saline treated with plasma for 30 and 40 s.
centrifuged and resuspended in plasma-activated saline (saline
treated by plasma for 30 or 40 s), followed by incubation for
30min at room temperature. Untreated S. aureus, or cells treated
with either plasma or plasma-activated saline (100 µl), were
plated on MH agar plates. Next, antibiotic susceptibility tests
were performed using Etest paper (Biomerieux) for tetracycline
(0.016–256µg/ml), gentamycin (0.016–256µg/ml), clindamycin
(0.016–256µg/ml), chloramphenicol (0.016–256µg/ml),
ciprofloxacin (0.02–32µg/ml), rifampicin (0.02–32µg/ml), and
vancomycin (0.016–256µg/ml) or the Kirby-Bauer method
for clindamycin (250, 500, 1,000, and 2,000 µg). Then the
plates were cultured overnight at 37◦C and bacteriostatic rings
were analyzed. The MICs of antibiotics were measured by the
microdilution assay using 8–0.016×MIC of untreated MRSA as
described (Lepe et al., 2014).
Quantification of Persister Survival
S. aureus treated with plasma or plasma-activated saline was
diluted six times with MH medium containing antibiotics.
The final antibiotic concentrations, corresponding to 10× the
minimum inhibitory concentration (MIC), were as follows:
tetracycline, 500µg/ml (MP Biomedicals); gentamycin,
200µg/ml (Sigma); clindamycin, 5,000µg/ml (TCI);
chloramphenicol, 500µg/ml (MP Biomedicals); ciprofloxacin,
50µg/ml (Sigma); rifampicin, 4µg/ml (Sigma); and vancomycin,
50µg/ml (Sigma). The numbers of surviving bacteria were
determined at the time points indicated by harvesting 100 µl
of bacterial culture, which was centrifuged at 10,000× g for
1min. The resulting pellet was resuspended in 100 µl 0.9%
NaCl. Samples were serially diluted, and 10 µl of each dilution
was spotted onto MH agar plates and incubated overnight at
37◦C and the numbers of surviving bacteria were determined by
counting the resulting CFUs.
Detection of Reactive Species in MRSA
The probes 3′-(p-aminophenyl) fluorescein (APF, Sigma),
3′-(p-hydroxyphenyl) fluorescein (HPF, Sigma), and MitoSOXTM
Red mitochondrial superoxide indicator (ThermoFisher) were
incubated with S. aureus cultures, at a final concentration
of 5µM, and trans-1-(2′-methoxyvinyl)pyrene (tMVP, J&K
Scientific) was used at a final concentration of 10µM at 37◦C
for 30min. Cultures were collected by centrifugation, washed
with saline (0.9% NaCl) three times and resuspended in saline
at an OD600 of 2.0. S. aureus suspensions were untreated,
treated with plasma directly for 40 s, or the suspensions
were centrifuged and resuspended in plasma-activated saline
(saline treated with plasma for 40 s). Immediately after
the treatments, the fluorescence intensities were detected
using a microplate reader (Thermo Scientific Varioskan
Flash) at the excitation and emission wavelengths [APF
and HPF: 490/515 nm; superoxide indicator: 510/580 nm;
trans-1-(2′-methoxyvinyl)pyrene: 405/460 nm] of each
probe.
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RESULTS
Plasma-Induced Aqueous ROS/RNS
MRSA or saline treated with the plasma device was shown
in Figure 1A. Gaseous ROS and RNS were generated by the
surface discharge, and some of them would diffuse across the
air gap and then dissolved into the liquids. The plasma-induced
aqueous ROS and RNS dissolved into saline were measured
after the plasma treatment for 30 s and 40 s. Long-lived species
H2O2, NO
−
2 , and NO
−
3 , as well as the short-lived species
•OH,
1O2,
•NO, and ONOO−, were detected in the saline. The
concentrations of aqueous H2O2, NO
−
2 , and NO
−
3 after the
plasma treatment for 40 s were 23, 14, and 102µM, respectively
(Figure 1B). Electron spin resonance (ESR) spectroscopy was
used for the measurement of short-lived species, in which the
results were the concentrations of spin adducts, only reflecting
the relative concentrations of the specific ROS and/or RNS. The
concentrations of spin adducts DMPO-OH, TEMPO, Nitrocyl-
Fe, and TEMPONE after the plasma treatment for 40 s were 0.1,
69, 21, and 37µM (Figure 1B). The spin adducts concentrations
after the plasma treatment for 30 s were lower, such as TEMPO
was 30% lower than that after the plasma treatment for 40 s.
These results suggested that the concentration of aqueous •OH
was very low, and the concentration of aqueous 1O2 should be
much larger. The plasma generated many species ROS and RNS,
which were thought to play a crucial role in the biological effects.
Sublethal Treatment With Plasma
Increased the Sensitivity of MRSA to
Antibiotics
The sublethal dose (reduction about 50% viability of MRSA) of
plasma and plasma-activated saline were determined by exposing
the bacteria to plasma for increasing times or incubating with
saline treated with plasma for increasing times and subsequently
determining bacterial viability. The treatment of plasma for 40 s
or the saline activated by plasma for 40 s lead to about 50% death
of MRSA cells (Figure S1). For safety, a lower dose was also
employed, so a slightly lower dose (plasma treatment for 30 s)
that lead to about 40% death of MRSA cells and the LD50 dose
(plasma treatment for 40 s) were both used to detect the effects
on antibiotic sensitivity.
To study the effect of plasma on the sensitivity of MRSA to
the antibiotics, MRSA were sublethally pre-treated with plasma
or plasma-activated saline followed by incubation with a range
of antibiotics including tetracycline, gentamycin, clindamycin,
chloramphenicol, ciprofloxacin, rifampicin, and vancomycin.
The minimal inhibitory concentration (MIC) of tetracycline for
untreated MRSAmeasured by Etest paper was∼32µg/ml, whilst
the MIC of tetracycline for MRSA treated with plasma for 30
or 40 s was 10-fold lower, at ∼3µg/ml (Figure 2A). In the
second approach, the MICs were measured by the microdilution
assay, and the MIC of tetracycline against MRSA treated with
plasma for 40 s was 8-fold lower than that against untreated
MRSA (Table 1). The effects of plasma pre-treatment on MRSA
sensitivity to antibiotics were independent of the particular
antibiotic used, and the increase in sensitivity was observed
for most of the antibiotics tested. The MICs of gentamycin
against untreated MRSA and MRSA treated with plasma for
30 and 40 s measured by Etest paper were ∼1.5, 1.0, and
0.5µg/ml, respectively, and the MIC of gentamycin against
MRSA treated with plasma for 40 s was 16-fold lower than
that against untreated MRSA as indicated by the microdilution
assay (Figure 2A; Table 1). The MICs of chloramphenicol,
ciprofloxacin, rifampicin, and vancomycin against MRSA treated
with plasma also decreased in varying degrees (Figure 2A;
Table 1). Plasma-treated MRSA did not appear to be susceptible
to treatment with clindamycin at the tested concentration
(Figure 2A). Two possible explanations for this were that either
the plasma treatment did not change the antibiotic sensitivity of
MRSA to clindamycin or the MIC of clindamycin against MRSA
was beyond the range of the Etest. Thus, MRSA susceptibility
to clindamycin was measured at a higher antibiotic dose using
the Kirby-Bauer method. The diameter of the bacteriostatic ring
of untreated MRSA to 2,000 µg clindamycin was about 16mm,
and that of the MRSA treated for 30 and 40 s were 23 and
26mm, respectively (Figures S2A,B). The microdilution assay
also demonstrated that the MICs of clindamycin against MRSA
treated with plasma for 30 and 40 s was 2- and 4-fold lower,
respectively, than that against untreated MRSA (Table 1). These
data indicated that sublethal plasma treatment to MRSA restored
the sensitivity to five different classes of antibiotics.
Next, the effects of plasma-activated saline upon changing
the sensitivity of MRSA to these antibiotics were detected.
The minimal inhibitory concentration (MIC) of tetracycline
against untreated MRSA was ∼32µg/ml, whilst that for MRSA
treated with saline activated by plasma for 30 or 40 s was 10-
fold lower, at ∼3µg/ml (Figure 2B). The MIC of tetracycline
against MRSA treated with saline activated by plasma for
40 s was also 8-fold lower than that against untreated MRSA
as indicated by the microdilution assay (Table 1). The MICs
of gentamycin, clindamycin, chloramphenicol, ciprofloxacin,
rifampicin, and vancomycin against MRSA treated with plasma-
activated saline were also lower than those against the untreated
MRSA, demonstrating that plasma-activated saline exhibited the
same effect in increasing the sensitivity to five different classes of
antibiotics (Figures 2B, Figures S2C,D; Table 1).
Plasma Pre-treatment Promoted
Eradication of MRSA Persisters
Given that pre-treatment of MRSA with plasma or plasma-
activated saline decreased the MIC of multiple antibiotics, we
next asked whether either of these pre-treatment conditions
could also promote the killing of persisters. To test this, untreated
and sublethal dose plasma-treated MRSA were incubated with
different antibiotics, as indicated (Figure 3A). Incubation of
untreated and double-diluted untreated MRSA with the different
antibiotics generally exhibited typical killing curves, with
bacterial numbers decreasing from 2× 108 to 104-106 CFUs, with
a small fraction of persisters detected after 3 days of antibiotic
exposure. Of note, the numbers of untreated MRSA and
double-diluted untreated MRSA that incubated with rifampicin
increased after 1 day. These results indicated that the decrease of
the initial MRSA numbers did not greatly influence the killing
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FIGURE 2 | Treatment with sublethal doses of plasma or plasma-activated saline increased the sensitivity of MRSA to antibiotics. (A) Direct plasma treatment.
(B) Plasma-activated saline treatment. Plasma treated, plasma-activated saline treated and untreated MRSA were plated on MH agar with Etest strips and cultured at
37◦C overnight.
TABLE 1 | Antibiotic susceptibilities of Staphylococcus aureus treated with plasma and plasma-activated saline.
Antibiotics MICa (mg/liter) of indicated antibiotic
Untreated Directly treated with
plasma for 30 s
Directly treated with
plasma for 40 s
Treated with plasma-activated
saline (Saline treated for 30 s)
Treated with plasma-activated
saline (Saline treated for 40 s)
Tetracycline 50 12.5 6.25 12.5 6.25
Gentamycin 20 2.5 1.25 1.25 1.25
Clindamycin 500 250 125 250 250
Chloramphenicol 50 25 12.5 25 25
Ciprofloxacin 5 1.25 0.31 1.25 0.625
Rifampicin 0.4 0.025 0.0125 0.025 0.0125
Vancomycin 5 5 2.5 5 2.5
aMICs were determined by broth microdilution method. The results were read after 24 h of incubation at 37◦C.
curves of antibiotics. In contrast, plasma-treatment reduced the
number of MRSA persisters to below the limit of detection
when incubated with tetracycline, gentamycin, clindamycin,
chloramphenicol, and rifampicin within only 1 day of exposure
(Figure 3A). A similar decrease was also observed within 2 and
3 days of incubation with ciprofloxacin and chloramphenicol,
respectively (Figure 3A). For vancomycin, plasma treatment
for 30 and 40 s effectively reduced the numbers of remaining
MRSA recovered during exposure to this antibiotic to 104 and
103 CFUs, respectively, though these did not drop below the
detection limit (Figure 3A). Treatment with plasma-activated
saline exhibited the same effect of inactivating persisters as
observed by direct plasma treatment (Figure 3B). The numbers
of plasma-activated saline treated MRSA recovered upon
Frontiers in Microbiology | www.frontiersin.org 5 March 2018 | Volume 9 | Article 537
Guo et al. Gas Plasma Increase Antibiotic Sensitivity
FIGURE 3 | MRSA sublethally treated with plasma or plasma-activated saline increased the eradication of persisters by antibiotics. (A) Direct plasma treatment.
(B) Plasma-activated saline treatment. Plasma treated, plasma-activated saline treated and untreated MRSA were grown in MHB with 10 × MIC of the indicated
antibiotics, and aliquots of the cultures were taken at the times indicated, serially diluted and plated. Then the plates were cultured at 37◦C overnight and the numbers
of bacteria were counted. The asterisks represented eradication to the limit of detection.
exposure to antibiotics tetracycline, gentamycin, clindamycin,
and rifampicin dropped to below the detection limit, but plasma-
activated saline similarly only decreased the numbers of MRSA
to 103 CFUs upon exposure to vancomycin (Figure 3B). These
results indicated that both plasma and plasma-activated saline
treatment promoted the eradication of MRSA persisters by
antibiotics.
Reactive Species in MRSA
Plasma-treated solutions contain many active species, such
as the long-lived species H2O2, NO
−
2 , and NO
−
3 as well as
the short-lived species •OH, 1O2,
•NO, O•−2 , and ONOO
−
(Figure 1B). To evaluate the impact of long-lived species,
a mixture of H2O2 (500µM), NO
−
2 (250µM), and NO
−
3
(750µM) was used to treat the MRSA. H2O2, NO
−
2 , and
NO−3 treatment did not change the antibiotic susceptibility
of MRSA and the inactivation of persisters by antibiotics,
indicating that the three long-lived species are not likely
the direct and driving factor (Figure S3). Hence, short-lived
species were considered more important, and the ROS and
RNS in MRSA cells were measured. MRSA were incubated
with 3′-(p-aminophenyl) fluorescein (APF) for •OH, ClO−,
and ONOO−, HPF for •OH and ONOO−, MitoSOX
TM
Red
mitochondrial superoxide indicator for O•−2 and trans-1-(2
′-
methoxyvinyl)pyrene (tMVP) for 1O2, then exposed to plasma
or plasma-activated saline for 40 s, and the levels of different
ROS/RNS determined by changes in the fluorescence intensities
(Figure 4). After plasma treatment, the fluorescence intensities
of the four probes increased. The fluorescence intensities of
MRSA incubated with APF and HPF increased slightly after
30min of plasma treatment, by 28 and 25%, respectively,
which indicates an increase in the levels of •OH, ClO−, and
ONOO− (Figures 4A,B). Fluorescence of MRSA incubated with
MitoSOXTM Red mitochondrial superoxide indicator increased
by 77%, and the trans-1-(2′-methoxyvinyl)pyrene (tMVP) for
1O2 increased by 130% after 30min of plasma treatment
(Figures 4C,D). The fluorescence intensities of the probes which
incubated with plasma-activated saline-treated MRSA were
slightly weaker than those of the direct plasma-treated samples.
These data suggested that the plasma and plasma-activated saline
treatment induced the increases of many species of ROS and RNS
in MRSA cells.
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FIGURE 4 | ROS and RNS levels increased in plasma-treated and plasma-activated saline-treated MRSA. MRSA incorporated with APF (A), HPF (B), superoxide
indicator (C), and tMVP (D), which measured the ROS or RNS as indicated, treated with plasma for 40 s or saline treated with plasma for 40 s. Then the fluorescence
intensities of were measured in plasma-treated, plasma-activated saline-treated, and untreated MRSA. Data are representative of three independent experiments.
Error bars represent s.d.
DISCUSSION
In this study, we demonstrated that treating MRSA sublethally
with plasma-generated ROS and RNS decreased the MICs of
several antibiotics and increased persister eradication, along with
increases in the levels of ROS and RNS in MRSA cells. Plasma-
activated saline had the same effect upon the antibiotic sensitivity
of MRSA and persister inactivation as direct plasma treatment,
suggesting that the plasma-generated ROS and RNS could be
applied in both gaseous or aqueous form depending on the mode
of application. The short-lived species in the plasma-activated
saline had short half-lives, but they could react and generate long-
lived species, which also could generate to short-lived species
reversibly, such as ONOO− generated from NO−3 (Oehmigen
et al., 2011; Liu et al., 2017). Plasma generated various ROS, which
are involved in a great many chemical reactions (Oehmigen et al.,
2011). The underlying reactions and detailed mechanisms of
plasma-activated saline are still not well understand and require
further study.
Unlike other treatments that have previously been used as
antibiotic adjuvants to enhance ROS production in bacterial
cells, plasma induces the production of a wider range of ROS
species (Morones-Ramirez et al., 2013; Shen et al., 2016). The
ROS and RNS generated by the plasma constitute a complex




ClO− (Liu et al., 2016). Subsequently, these many different
ROS or RNS species were also detected in plasma-treated
bacterial cells. The intracellular ROS and RNS could induce
oxidative stresses, such as damaging lipids, proteins and DNA
by •OH, 1O2, and O
•−
2 , as well as protein damages by
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ONOO− and ClO− (Davies, 2016). O•−2 could be detoxified
by endogenous antioxidants of the oxidative response, but
no enzyme can detoxify •OH or 1O2, and MRSA could not
detoxify all the multiple reactive species induced by plasma
(Vatansever et al., 2013). It was speculated that the compound
damages stimulated multiple response pathways and kept
MRSA busy with repairing, which contributed to the effects of
antibiotics.
Reactive species generated by plasma could also induce
damages in eukaryotic cells, subsequently, the safety and toxicity
of this application should be considered. The CC50 of the
plasma treatment used in this study for human primary
dermal fibroblasts was about 40 s treatment, which was close
to the LD50 on MRSA (Figure S4A). Comparing with bacterial
cells, the cultured cells are more easily to be inactivated in
vitro because of the lack of cell wall. However, the plasma
treatment did not increase micronuclei formation in fibroblast
cells (Figures S4B,C). Coincidently, a newly published paper
found similar results on lymphocyte TK6 cells (Bekeschus
et al., 2018). Further, the olive tail moment of plasma-treated
cells exhibited little difference with that of untreated cells
(Figures S4D,E). So the plasma treatment did not remarkably
increase the mutagenicity of fibroblasts as demonstrated by
both micronucleus assay and comet assay. Besides, Maisch
et al. (2012) showed that gas plasma could efficiently inactivate
S. aureus and Escherichia coli on pig skin without inducing
morphological changes or damage-related apoptosis. Clinical
trials also demonstrated that 5min daily treatment with plasma
decreased bacteria in chronic wounds of patients without side
effects (Isbary et al., 2010). These studies demonstrated the
safety of plasma treatment under limited conditions. Many
topical biocides are toxic, and the plasma could be developed
as alternative, especially the plasma-activated saline could be
the save alternative (Wales and Davies, 2015). When used as
a sensitizer with antibiotics as was done in this study, the
doses of plasma were much lower than that used for bacteria
inactivation, which would reduce the risk of toxicity and improve
the safety.
In conclusion, sublethal treatment with plasma-generated
ROS and RNS decreased the MICs of several antibiotics and
increased persister eradication, along with increases in the levels
of ROS and RNS in MRSA. Plasma and plasma-activated saline
could be explored as a novel antibiotic sensitizer to generate
oxidative stress to combat the increasing problem of antibiotic
resistance. Further studies are needed to test these methods
against other multidrug-resistant bacteria and to elucidate the
underlying mechanism.
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